Anemia is a significant problem for cancer patients, especially those receiving chemotherapy. Preventing or treating anemia in these patients has clear cut quality of life improvements for the patients AND their care givers. Glaspy et al. furthermore tackle the important issue of survival and venous thromboembolism in their review article. They convincingly make the case […]
A restrictive use of both autologous donation and recombinant human erythropoietin is an efficient policy for primary total hip or knee arthroplasty.
Finally a paper which tries to tell us when not to use these expensive modalities. Predonation and erythropoetin are essential tools in the reduction of allogeneic transfusion but their precise role is still being defined. Here are some tips on how to use them more efficiently. A very useful paper. – Peter Earnshaw
Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial.
This study by Henke et al. is certainly provocative. It reports a poor disease free and overall survival in head and neck cancer patients receiving locoregional radiation therapy. What might explain this negative tumor and overall survival effect in this erythropoietin study when virtually every other erythropoietin study has not had such an observation? First […]
Recombinant human erythropoietin, epoetin beta, in patients with relapsed lymphoma treated with aggressive sequential salvage chemotherapy – results of a randomized trial.
This positive study demonstrated that epoetin patients did better than no epoetin control patients in a relapsed lymphoma, autologous stem cell transplant setting. Epoetin has been shown not to be very effective in the high dose chemotherapy stem cell transplant setting when given only at the time of transplant and high dose chemorx. As demonstrated […]
Response predicting factors to recombinant human erythropoietin in cancer patients undergoing platinum-based chemotherapy.
This is a well done study of anemic cancer patients on cisplatin chemotherapy that documents nicely that the best predictor of an ultimate good response to epoetin is an early response to epoetin… in this case at 4 weeks. Sadly, we still know that about two thirds of patients respond, but we cannot predict at […]